Related Experiment Video
Updated: Jun 26, 2026

Long Term Chronic Pseudomonas aeruginosa Airway Infection in Mice
Published on: March 17, 2014
Clinical cure of ventilator-associated pneumonia treated with piperacillin/tazobactam administered by continuous or
Leonardo Lorente1, Alejandro Jiménez, María M Martín
1Intensive Care Unit, Hospital Universitario de Canarias, Ofra s/n, La Cuesta, La Laguna 38320, Tenerife, Spain. lorentemartin@msn.com
Abstract:
The standard mode of administration of piperacillin treatment is by intermittent infusion. However, continuous infusion may be advantageous as beta-lactam antibiotics exhibit time-dependent antibacterial activity. In previous studies, we found a higher rate of clinical cure of ventilator-associated pneumonia (VAP) by continuous infusion rather than intermittent infusion of meropenem and ceftazidime. Therefore, the objective of this historical cohort study was to establish the clinical efficacy of piperacillin/tazobactam (PIP/TAZ) administered by continuous and intermittent infusion in the treatment of VAP in patients without renal failure. Logistic regression analysis showed a higher probability of clinical cure of VAP by continuous compared with intermittent infusion when the microorganism responsible for VAP had a minimum inhibitory concentration (MIC) of 8 microg/mL [8/9 (88.9%) vs. 6/15 (40.0%); odds ratio (OR)=10.79, 95% confidence interval (CI) 1.01-588.24; P=0.049] or 16 microg/mL [7/8 (87.5%) vs. 1/6 (16.7%); OR=22.89, 95% CI 1.19-1880.78; P=0.03]. Thus, administration of PIP/TAZ by continuous infusion may be considered more effective than intermittent infusion for the treatment of VAP caused by Gram-negative bacteria when the MIC of the microorganism responsible for VAP is 8-16 microg/mL in patients without renal failure.
Insights
Continuous infusion of piperacillin/tazobactam (PIP/TAZ) demonstrated higher clinical cure rates for ventilator-associated pneumonia (VAP) compared to intermittent infusion, especially for Gram-negative bacteria with specific minimum inhibitory concentrations.
Area of Science:
- Pharmacology
- Infectious Diseases
- Critical Care Medicine
Background:
- Piperacillin/tazobactam (PIP/TAZ) is commonly administered via intermittent infusion for bacterial infections.
- Beta-lactam antibiotics, including PIP/TAZ, exhibit time-dependent activity, suggesting continuous infusion may improve efficacy.
- Previous studies indicated superior outcomes with continuous infusion of other beta-lactams for ventilator-associated pneumonia (VAP).
Purpose of the Study:
- To compare the clinical efficacy of continuous versus intermittent infusion of PIP/TAZ in treating VAP.
- To evaluate the impact of minimum inhibitory concentration (MIC) on treatment outcomes.
- To assess efficacy in patients without renal failure.
Main Methods:
- Historical cohort study design.
- Analysis of clinical cure rates for VAP patients treated with PIP/TAZ via continuous or intermittent infusion.
- Logistic regression analysis to determine the association between infusion method, MIC, and clinical cure.
Main Results:
- Continuous infusion showed a significantly higher probability of clinical cure for VAP when the causative microorganism had an MIC of 8 or 16 microg/mL.
- Odds ratios favored continuous infusion, particularly at higher MICs (OR=10.79 for MIC 8, OR=22.89 for MIC 16).
- Treatment success rates were substantially higher with continuous infusion (88.9% vs. 40.0% for MIC 8; 87.5% vs. 16.7% for MIC 16).
Conclusions:
- Continuous infusion of PIP/TAZ may be more effective than intermittent infusion for treating VAP caused by Gram-negative bacteria with MICs of 8-16 microg/mL in non-renal failure patients.
- Optimizing antibiotic administration strategies, such as continuous infusion, can improve VAP treatment outcomes.
- Further research may explore the role of pharmacokinetic/pharmacodynamic optimization in VAP management.
Related Concept Videos
Pneumonia IV: Management
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
Pulmonary Tuberculosis V
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the progression...
Pneumonia V: Nursing management and Prevention
The nurse must practice strict medical asepsis and adhere to infection control guidelines to minimize healthcare-associated infections.
Enhance airway patency
Position the patient correctly to facilitate drainage of the affected lung segments. Manual or mechanical percussion and vibration can also be employed.
Pneumonia I: Introduction
Risk Factors
Various factors influence the likelihood of developing pneumonia. Age plays a crucial role, with infants, children under two, and individuals over 65 at increased risk due to their...
Pneumonia I: Introduction
Pulmonary Tuberculosis IV
Several diagnostic approaches are used to detect TB. The conventional method is the Tuberculin Skin Test (TST), also known as the Mantoux test. However, this method has...